Suven Life Sciences has secured 3 product patents for their New Chemical Entities (NCEs), one product patent from South Korea, one product patent from China and one product patent from Canada corresponding to the NCEs for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2029, 2029 and 2031 respectively.
The granted claims of the patents include the class of selective 5-HT compounds discovered by the company and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.
With these new patents, the company has a total of fourteen granted patents from South Korea, fourteen granted patents from China and sixteen product patents from Canada. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.
